Update 2021; Immunization, Vaccines and Biologicals
DHS Working Papers No. 108 | Zimbabwe Working Papers
No. 9
Antimicrobial resistance (AMR) is a major public health challenge, which is recognized as high priority area by the Government of India. The increasing consumption of antibiotics is one of the key drivers of antimicrobial resistance seen in bugs of public health importance. Irrational prescription o...f broad-spectrum antibiotics, poor regulations around sale of antibiotics, self-medication, lack of education and awareness regarding responsible use of antibiotics have been identified as some of the key factors driving antimicrobial resistance in our country. The ‘National Health Policy’ (2017), addresses antimicrobial resistance as one of the key issues and prioritises development of guidelines regarding antibiotic use, limiting the over-the-counter use of antibiotics, restricting the use of antibiotics as growth promoters in livestock, and pharmaco-vigilance including prescription audit inclusive of antibiotic usage in the hospital and community.
more
Guideline
SAJHIVMED DECEMBER 2013, Vol. 14, No. 4
Integritas 4.3 (Fall 2014), pp. 1-30.
doi: 10.6017/integritas.v4i3p1
The Mtoto Mwerevu Stunting Reduction Toolkit is a resource for government and organisations involved in addressing stunting and broader nutrition issues in Tanzania. The toolkit was developed in conjunction with the Government of Tanzania (GoT) with funding from UK Aid as part of the Addressing Stun...ting in Tanzania Early (ASTUTE) programme. Its goal is to provide government, donors, non-governmental organisations, and civil society organisations (CSOs) with programming recommendations and tools to help implement successful multi-sectoral social and behaviour change (SBC) interventions aimed at preventing and reducing stunting.
more
Временные рекомендации
9 августа 2021 г.
Цель данного документа - описать минимальный набор мероприятий по эпиднадзору, рекомендуемых на национальном уровне для вы...вления и мониторинга относительной распространенности вариантов SARS-CoV-2, и наметить набор мероприятий для характеристики и оценки риска, создаваемого этими вариантами. Также приводится набор показателей для стандартизации мониторинга и публичной отчетности о циркуляции вариантов.
Документ предназначен в первую очередь для национальных и субнациональных органов здравоохранения и партнеров, поддерживающих внедрение эпиднадзора за вариантами SARS-CoV-2.
more
Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotic.
The Standard, facilitated by BSI Standards Limited (BSI), provides clear guidance to manufacturers in the global antibiotic supply chain to ensure t...hat their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment.
more
This project aimed to reduce the risk of vector-borne infection with Chagas disease by
controlling triatomine bugs, the vectors transmitting the parasite of Chagas disease, and
establishing an epidemiological surveillance system with community participation.
Asthma Action Plan
Doctor’s Name:
Doctor’s Phone Number:
Main Emergency Contact:
Backup Emergency Contact:
Green Zone: No coughing, wheezing, chest tightness, or shortness of breath.
Can do usual activities:
Every day: Take these medicines, even if you’re not having any symptoms.
Av...oid triggers that you know make your asthma worse.
Medicine: / How much to take: / When to take:
Before you exercise: Take 2 or 4 Puffs of_____ 5 minutes before you start, as needed.
...
more
Examining the infrastructure of the Russian and USA healthcare systems with respect to the management of HIV patients
Communicable Disease Control Branch
Communicable Disease Management Protocol – Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS), February 2010
New funding requirements: CHF 2.8 billion IFRC-wide of which CHF 670 million is channelled through the IFRC Emergency Appeal in support of National Societies
This global guidance provided the framework for over 100 countries to develop their NDVPs. This updated (second) version supersedes the previous version published in 16 November 2020. New information has been added on the following areas:
the COVID-19 Partners Platform;
the use of COVID...-19 simulation exercises to test deployment strategies;
the indemnity agreement and no-fault compensation programme for vaccines secured through the COVAX Facility in the Advance Market Commitment (AMC) eligible economies;
the availability and use of the WHO-UNICEF COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool;
the COVAX Facility’s humanitarian buffer that enables allocation of vaccine to cover high-risk populations in humanitarian settings;
recommendations for vaccination of pregnant and lactating women;
supplementary information on infection prevention and control (IPC) measures to be used to deliver COVID-19 vaccines safely;
the WHO licensed COVID-19 vaccines product-specific information;
use of geospatial data and digital micro plans for equitable access and delivery of COVID-19 vaccines;
lessons learned from the development of NDVPs and early experiences in COVID-19 vaccine deployment in countries; and
updated additional resources at the end of each chapter.
more